Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease - Full Text View

Purpose

We aimed to evaluate the hypothalamus-pituitary-adrenal axis in autosomal dominant polycystic kidney disease (ADPKD) patients. Twenty two ADPKD patients and 27 healthy subjects were enrolled.

Condition	Intervention
Autosomal Dominant Polycystic Kidney Disease	Drug: Tetracosactin


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Diagnostic
Official Title:	Assessment of Adrenal Functions in Patients With Autosomal Dominant Polycystic Kidney Disease

Resource links provided by NLM:

Genetics Home Reference related topics: polycystic kidney disease

MedlinePlus related topics: Kidney Diseases

Drug Information available for: Racepinephrine Cosyntropin

U.S. FDA Resources

Further study details as provided by Istanbul University:

Primary Outcome Measures:

Inadequate response to tetracosactin infusion [ Time Frame: 30 and 60 minutes after the drug is administered ]


Enrollment:	49
Study Start Date:	September 2006
Study Completion Date:	September 2007
Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: 1 Patients with autosomal dominant polycystic kidney disease	Drug: Tetracosactin 1 microgram tetracosactin, intravenous injection, once for the test Other Name: Synacthen
Active Comparator: 2 Healthy subjects	Drug: Tetracosactin 1 microgram tetracosactin, intravenous injection, once for the test Other Name: Synacthen

Detailed Description:

CONTEXT: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and extrarenal manifestations may be observed in many organ systems. Hypothalamus-pituitary-adrenal axis in patients with ADPKD was not evaluated extensively.

OBJECTIVE: We aimed to evaluate the hypothalamus-pituitary-adrenal axis in ADPKD patients.

METHODS: Twenty two ADPKD patients and 27 healthy subjects were enrolled. Basal dehydroepiandrosterone-sulfate (DHEAS) levels and cortisol and dehydroepiandrosterone responses to low dose short adrenocorticotropin stimulation test were assessed. Correlation analyses of these parameters with glomerular filtration rates, renal volumes and pain characteristics in patients with ADPKD were done.

Eligibility


Ages Eligible for Study:	20 Years to 56 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Healthy subjects
Diagnosis of autosomal dominant polycystic kidney disease

Exclusion Criteria:

A glomerular filtration rate below 60 ml/min
History of recent major surgery
Systemic infections with fever
Significant hirsutism (Ferriman Gallwey score≥8)
Congenital adrenal hyperplasia
Late onset congenital adrenal hyperplasia
Systemic corticosteroid use (including previous use)
Topical corticosteroid use
Menstrual irregularity
History of thromboembolism
Uncontrolled diabetes or hypertension
History of psychosis
Pregnancy
Lactation
History of hypersensitivity to tetracosactin

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00598377

Locations


Turkey
Istanbul Univetsity, Istanbul Medical Faculty, Department of Internal Medicine
Istanbul, Turkey, 34390

Sponsors and Collaborators

Istanbul University

Investigators


Principal Investigator:	Tevfik Ecder, Professor	Istanbul University, Istanbul Medical Faculty, Department of Internal Medicine, Division of Nephrology
Study Director:	Fatih Tufan, Fellow	Istanbul University Istanbul Medical Faculty Department of Internal Medicine
Study Director:	Neşe Çolak, Professor	Istanbul University Istanbul Medical Faculty Department of Internal Medicine Division of Endocrinology
Study Chair:	Bora Uslu, Fellow	Istanbul University Istanbul Medical Faculty Department of Internal Medicine
Study Chair:	Kültigin Türkmen, Fellow	Istanbul University Istanbul Medical Faculty Department of Internal Medicine
Study Chair:	Mükremin Uysal, Fellow	Istanbul University Istanbul Medical Faculty Department of Internal Medicine
Study Chair:	Nilüfer Alpay, Fellow	Istanbul University Istanbul Medical Faculty Department of Internal Medicine
Study Director:	Rian Dişçi, Professor	Istanbul University Istanbul Medical Faculty Department of Public Health
Study Chair:	Bledi Çerkezi, Fellow	Istanbul University Istanbul Medical Faculty Department of Radiology

More Information


Responsible Party:	Tevfik Ecder, Istanbul University, Istanbul Medical Faculty, Division of Nephrology
ClinicalTrials.gov Identifier:	NCT00598377 History of Changes
Other Study ID Numbers:	2007/233
Study First Received:	December 31, 2007
Last Updated:	February 17, 2009

Keywords provided by Istanbul University:


Autosomal dominant polycystic kidney disease Adrenal functions Renal volume Glomerular filtration rate Adrenal Cortex Function Tests

Additional relevant MeSH terms:


Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Dominant Urologic Diseases Kidney Diseases, Cystic Epinephrine Racepinephrine Epinephryl borate Cosyntropin Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents	Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic beta-Agonists Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Mydriatics Sympathomimetics Vasoconstrictor Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on May 23, 2017